Interim
Leadership
Deep Domain
Expertise
De-risk Commercialization
Clarity AI HITL Commercial Workflow
Experienced Leadership
Team
1. Launching a Rare Disease Company in Canada
Challenge:
A global pharma leader needed to launch a dormant rare disease treatment in Canada, which lacked any local medical or commercial infrastructure.
Our Approach:
We built the entire Canadian operation from the ground up, establishing the medical affairs and patient support infrastructure, creating a market-access strategy, and executing a tailored commercial launch.
Result:
Canada became the company's top-performing global affiliate, leading to full local independence and contributing to a major strategic acquisition. This case highlights our ability to execute full-scale, go-to-market transformations in highly specialized therapeutic areas.
View Rare Disease Company Launch
2. Scaling a Digital Health Platform for Acquisition
Challenge:
A continuing health education (CHE) platform struggled with physician skepticism and limited adoption, hindering its growth and exit potential.
Our Approach:
We optimized the platform, curated high-value content from Key Opinion Leaders (KOLs), and executed targeted growth campaigns to build credibility and drive user adoption across hospitals and associations.
Result:
The platform achieved rapid user adoption and was successfully acquired by a major healthcare education provider, demonstrating its lasting value. This case shows our expertise in scaling digital health ventures for successful exits.
Case Study
Disrupting a 59-Year Diagnostic Laboratory Monopoly
From market challenger to national presence in 18 months
The Challenge
A U.S.-based diagnostics lab entered the Canadian market long dominated by a single player. Strategic Growth AI delivered a comprehensive market entry strategy that transformed industry skepticism into widespread adoption, establishing the lab as a credible, trusted alternative.
Roadblocks We Overcame:
-
Market Resistance: Clients were deeply tied to the incumbent provider
-
Logistics Complexity: Vast geography + limited couriers raised delivery costs
-
Regulatory Barriers: Provincial + federal compliance requirements
-
Operational Scaling: Fast onboarding without compromising quality
-
Credibility Gap: Breaking 59 years of institutional loyalty required flawless execution
Results Achieved:
-
1,700+ client sites secured across Canada
-
Significant revenue growth via strategic partnerships
-
Market credibility as the first serious challenger in 6 decades
-
Operational scalability for long-term growth and excellence
Bottom Line: Our client became Canada's fastest-growing diagnostics company, proving that focused execution beats legacy dominance.
Strategic Growth AI was purpose-built to improve outcomes for healthcare and AI companies.
What Studies Indicate
ROI Potential
-
Analyses of specialized consulting in healthcare report meaningful positive returns
-
Case ranges up to ~7:1 in select contexts.[1,3,5] Results vary by scope, baseline, and execution.
Expertise Correlates with Outcomes
-
Multiple studies find a statistically significant positive relationship between consultant specialization and project success.[1,3]
Generalist Risk
-
An NHS analysis reported efficiency declines (≈3.5–8%) when generalist approaches were used in certain settings.[2]
Why It Matters for You
-
Regulatory-First Product Market Fit
-
Evidence and intended-use locked early → fewer rework cycles, faster path to payer-backed revenue.
-
Payer-Grade Proof: HEOR, VOI, and coverage strategy tied to codes, sites of care, and price realization.
-
Operator Execution: BOT/fractional teams that translate strategy into paid claims, contracts, and measurable cash.
References (map these to live links in the final page)
-
Expert Power for Consultants and Client Outcomes, PMC, 2025.
-
Management Consultants and NHS Efficiency, 2017–2022, NHS England longitudinal study.
-
Healthcare Performance Frameworks, BMC Health Serv Res, 2020.
-
Global Healthcare Consulting Market, Markets and Markets, 2025.
-
Deloitte Pharma R&D Return on Investment Study, 2023.
Unified Disclosure & Method Notes
* Strategic Growth AI (“SGAI”) provides advisory services only. Evidence summaries draw on peer-reviewed, governmental, and industry sources and third-party studies (circa 2020–2025) believed reliable but not warranted. Healthcare markets are affected by regulatory, competitive, and macroeconomic changes; forward-looking statements are not guarantees of future performance. Outcomes depend on client decisions, capabilities, data quality, and external factors outside SGAI’s control. Past results and benchmarks do not guarantee future results. Any ROI figures are contextual and illustrative and will vary by organization size, complexity, implementation fidelity, and market conditions. Nothing herein is legal, medical, tax, or investment advice.
Evidence-informed, multiplicative risk model that quantifies how coordinated controls across regulatory, evidence, economics, and execution (proprietary weighting/sequence) cut residual failure risk and accelerate coverage velocity (payer wins/quarter).
4 risk domains covered
-
Scientific: efficacy/safety, endpoints, trial design, manufacturability.
-
Commercial: market access, coding/pricing, payer requirements, GTM/adoption.
-
Operational: team gaps, timelines, compliance/quality, resource allocation.
-
Financial: capital cadence, cash-flow reliability, revenue/margin realism, exit timing.
How it works (strategy → controls → measurable delta)
-
Baseline diligence: PoS, coverage gaps, code/path analyses.
-
Control levers & sequencing: intended-use/endpoint lock-in → RWE pilots → payer sequencing → coding/pricing ops.
-
Operator execution (BOT/fractional): milestones, gates, KPIs, variance control.
-
Portfolio logic (for funds): kill/accelerate by risk-adjusted value.
Forecast before you commit
Scenario projections, rNPV/IRR/MOIC, PoS bands, burn-multiple trajectory → align capital, milestones, and timing with risk-adjusted upside.
Who uses it & why
VCs/investors, pharma/biotech, medtech/diagnostics, AI-health/SaMD, SMBs/enterprises, to re-price risk, pick fastest pathways, and convert pilots to paid claims.
Illustrative impact (not guarantees)
Milestone odds:
-
~1.5×–2.3× improvement with layered controls
Time-to-first paid claim
-
~10–30% faster with RWE/CED + payer sequencing
Spend avoidance
-
~15–35% via regulatory-first PMF and right-sized pilots
Risk Reduction
-
In select scenarios: up to ~60 pp reduction in failure risk
What you receive
-
Baseline risk posture (literature-anchored PoS, evidence/coverage gaps)
-
Modeled deltas (pre/post PoS bands, time-to-coverage)
-
90-day operator plan with milestones, gates, KPIs
SGAI Advantage
Startup survival increased: 2.5×–3×
Dev & GTM costs decreased: 25%–42%
Follow-on success increased: 2×–3×.
CTA: Book Your Strategy Call
Figures are illustrative, evidence-informed; outcomes vary by asset and execution.
Language of Venture Capital
To secure funding, AI and health-tech startups must prove more than technological promise, they need to demonstrate capital efficiency and a clear path to profitability. We embed investor-grade metrics into every engagement to build confidence and unlock funding.
Burn Multiple
-
We help companies drive toward a best-in-class burn multiple by focusing on capital efficiency.
-
While the median for SaaS is around 1.6x, we implement strategies to push this below 1.5x
ARR per Employee
-
A key measure of operational leverage.
-
We help clients build lean, effective teams that outperform the typical $200k+ benchmark for mature companies
Customer Lifetime Value (CLV) to CAC Ratio
-
We focus on building sustainable growth models that target a CLV:CAC ratio of 3:1 or better
Quantifying Risk, Prioritizing Controls, and Proving Commercial Value
Executive Summary
SGAI integrates Monte Carlo simulation with the SGAI Predictable De-Risking Model (SGAI-PDM™) to replace opinion with quantified probabilities. We model uncertainty across regulatory, evidence, economics, and execution to produce risk-adjusted outcomes.
What Monte Carlo Provides:
A computational technique that runs thousands of 'what-if' simulations using probability distributions for uncertain inputs. The output is a distribution of outcomes: likelihood of success, time-to-coverage, time-to-revenue, risk-adjusted NPV, and MOIC bands.
Integration with SGAI-PDM™:
SGAI-PDM™ is a multiplicative control model where Monte Carlo applies distributions to baselines and control effects, producing probability bands rather than point claims. This reveals which control sequences maximize probability of success and compress time-to-coverage.
Stakeholder Benefits:
-
Venture Capital: Portfolio survival & MOIC distributions; compare pre/post SGAI engagement
-
Physicians/KOLs: Adoption & protocol-deviation probabilities; impact of RWE on guideline inclusion timelines
-
Startups: Runway and survival bands under funding/velocity scenarios
-
SMBs: Time-to-revenue and cash-flow distributions under access strategies
-
Enterprises: Phase-transition probabilities and portfolio allocation optimization
In life sciences, AI-health, and healthcare, even well-capitalized companies are being stalled, not by lack of innovation, but by avoidable risk, inefficient execution, and capital misalignment. Model-Based Cost Avoidance and Predictable De-Risking are now essential for turning planning into proactive defense, reducing burn, and aligning execution with ROI from day one.
How It Works:
-
Cost Avoidance Map: Tailored analysis of where capital is typically wasted, and how to avoid it
-
Execution Scenarios: Side-by-side modeling of timelines, team builds, and regulatory plans
-
Commercial Sprints: Milestone-based delivery designed to move you from lab to launch faster
-
AI-Augmented Forecasting: Real-time insights and automated risk modeling with our Clarity AI™ framework
Expected Outcomes:
Typical clients reduce avoidable costs, improve funding readiness, and accelerate market entry without increasing headcount
Why It Matters Now:
-
Capital Efficiency is Non-Negotiable: Funding is harder to secure and slower to arrive
-
Failure Modes Are Predictable: Delays, mis-hires, flawed GTM sequencing, and payer pushback can be forecasted and avoided
-
Investors Expect More Than Vision: They want scenario planning, rNPV modeling, IRR clarity, and structured risk-return strategy
-
AI Enables Real-Time Forecasting: Our Clarity AI framework combines benchmarks, human insight, and automation
-
Execution Gaps are the #1 Threat: Poor alignment between regulatory, commercial, and ops is the leading cause of launch failure
General Disclaimers
-
No Guaranteed Results: Strategic Growth AI provides decision-support services. We do not guarantee outcomes. The case studies, testimonials, and metrics presented represent past results and are not a guarantee of future performance for other clients. All forecasts are illustrative scenario analyses based on stated assumptions and client inputs; actual results may differ materially.
-
Not Financial or Legal Advice: The information provided on this website, including in our blog, articles, and reports, is for educational and informational purposes only. It is not intended as, and shall not be understood or construed as, financial, legal, tax, or medical advice. You should consult with a professional in the respective field for advice tailored to your specific situation.
-
Testimonials Disclaimer: Testimonials and success stories reflect the real-life experiences of individuals and companies we have worked with. However, results are not typical and will vary based on a variety of factors including the client's business, effort, and market condition.